Navigation Links
VirtualScopics to Present at Two Upcoming Investor Conferences
Date:11/3/2008

ease that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the Company's investment in infrastructure and new customer contract signings and awards in 2008 and/or statements preceded by, followed by or that include the words "believes," "could," "expects," "anticipates," "estimates," "intends," "plans," "projects," "seeks," or similar expressions. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Many of these risks and uncertainties are discussed in the Company's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2007 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent reports filed with the SEC, all of which are available at the SEC's website at http://www.sec.gov. These include without limitation: the risk of cancellation or delay of customer contracts or specifically as it relates to contact awards, the risk that they may not get signed. Other risks include the company's dependence on its largest customers and risks of contract performance, protection of our intellectual property and the risks of infringement of the intellectual property rights of others. All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements.

CONTACT: Company Contact:

Molly Henderson


'/>"/>

SOURCE VirtualScopics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. VirtualScopics Schedules Third Quarter 2008 Earnings Announcement
2. VirtualScopics Reports Second Quarter 2008 Results
3. VirtualScopics Receives NASDAQ Delisting Notice; Company Files Appeal to Stay Delisting
4. VirtualScopics Backlog Exceeds a Record $20 Million
5. VirtualScopics Announces $4.35 Million Private Placement
6. Tibotec presents interim findings for TMC435, an investigational genotype 1 hepatitis C treatment
7. BioCryst to Present at the Rodman and Renshaw 10th Annual Healthcare Conference
8. LCA-Vision to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
9. NMB's Fans and Blowers to be Represented in Canada by CST-Arwin
10. The Ensign Group to Present at the Oppenheimer 19th Annual Healthcare Conference
11. Satellite Healthcare Will Present at the American Society of Nephrology's Renal Week – Booth 527 : November 4-9, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Helping to Clear the Air for Consumers - New Certification Standard for HEPA Filters Will Help Millions of People Make More Educated Choices 2Health News:SAFC Supply Solutions Introduces Certified Organics to Flavors & Fragrances Product Line 2Health News:SAFC Supply Solutions Introduces Certified Organics to Flavors & Fragrances Product Line 3Health News:SAFC Supply Solutions Introduces Certified Organics to Flavors & Fragrances Product Line 4Health News:Official Launch of ABLE TO CHOOSE Public Awareness Campaign 2Health News:Breast Cancer Action Victorious in Yoplait 'Pinkwashing' Campaign 2Health News:During National Wise Health Consumer Month: Consumers Seek Cost-Effective Health Care 2Health News:During National Wise Health Consumer Month: Consumers Seek Cost-Effective Health Care 3Health News:During National Wise Health Consumer Month: Consumers Seek Cost-Effective Health Care 4Health News:During National Wise Health Consumer Month: Consumers Seek Cost-Effective Health Care 5Health News:Autism Consortium members publish in PNAS: Mechanism, treatment for Rett syndrome -- top cause autism girls 2Health News:Autism Consortium members publish in PNAS: Mechanism, treatment for Rett syndrome -- top cause autism girls 3
Breaking Medicine Technology:FDA Launches Orphan Drug Workshop at KGI 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 3BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 4TNF-Alpha Inhibitors Are Being Used More Often To Treat Newly Diagnosed Patients With Crohn's Disease 2TNF-Alpha Inhibitors Are Being Used More Often To Treat Newly Diagnosed Patients With Crohn's Disease 3MoviMED Announces Participation in NIWeek 2009 Conference to Examine Trends and Technologies for Boosting Productivity and Increasing Competitive Adva 52876 1MoviMED Announces Participation in NIWeek 2009 Conference to Examine Trends and Technologies for Boosting Productivity and Increasing Competitive Adva 52876 2MoviMED Announces Participation in NIWeek 2009 Conference to Examine Trends and Technologies for Boosting Productivity and Increasing Competitive Adva 52876 3Huntsville Alabama Plastic Surgeon David L Durst MD Comments on Silicone Breast Implants after Nearly 3 Years on the Open Market 52871 1Huntsville Alabama Plastic Surgeon David L Durst MD Comments on Silicone Breast Implants after Nearly 3 Years on the Open Market 52871 2Huntsville Alabama Plastic Surgeon David L Durst MD Comments on Silicone Breast Implants after Nearly 3 Years on the Open Market 52871 3FDA Issues Complete Response Letter for INTUNIV 28TM 29 28guanfacine 29 Extended Release for the Treatment of ADHD in Children and Adolescents 4786 1FDA Issues Complete Response Letter for INTUNIV 28TM 29 28guanfacine 29 Extended Release for the Treatment of ADHD in Children and Adolescents 4786 2FDA Issues Complete Response Letter for INTUNIV 28TM 29 28guanfacine 29 Extended Release for the Treatment of ADHD in Children and Adolescents 4786 3FDA Issues Complete Response Letter for INTUNIV 28TM 29 28guanfacine 29 Extended Release for the Treatment of ADHD in Children and Adolescents 4786 4FDA Issues Complete Response Letter for INTUNIV 28TM 29 28guanfacine 29 Extended Release for the Treatment of ADHD in Children and Adolescents 4786 5FDA Issues Complete Response Letter for INTUNIV 28TM 29 28guanfacine 29 Extended Release for the Treatment of ADHD in Children and Adolescents 4786 6